You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMidazolam
Accession NumberDB00683  (APRD00680)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.
Structure
Thumb
Synonyms
Buccolam
Dormicum
Midazolam
Midazolamum
External Identifiers
  • Dea No. 2884
  • Ro 21-3981/001
  • Ro 21-3981/003
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BuccolamSolution2.5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution7.5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution10 mgBuccalShire Services Bvba2011-09-05Not applicableEu
Midazolam InjectionSolution1 mgIntramuscular; IntravenousPfizer Canada Inc2015-03-31Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousPfizer Canada Inc2015-03-31Not applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam InjectionLiquid5 mgIntramuscular; IntravenousFresenius Kabi Canada Ltd2001-03-26Not applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousFresenius Kabi Canada Ltd2001-03-26Not applicableCanada
Midazolam Injection BPSolution1 mgIntramuscular; IntravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Midazolam Injection BPSolution5 mgIntramuscular; IntravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Midazolam Injection SdzSolution1 mgIntramuscular; IntravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Midazolam Injection SdzSolution5 mgIntramuscular; IntravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Midazolam Injection USPSolution1 mgIntramuscular; IntravenousHospira Healthcare Corporation2015-03-30Not applicableCanada
Midazolam Injection USPSolution5 mgIntramuscular; IntravenousHospira Healthcare Corporation2016-02-09Not applicableCanada
Midazolam Injection USPSolution5 mgIntramuscular; IntravenousHospira Healthcare Corporation2016-02-16Not applicableCanada
Midazolam Injection USPSolution1 mgIntramuscular; IntravenousHospira Healthcare Corporation2016-06-15Not applicableCanada
PMS-midazolamLiquid1 mgIntramuscular; IntravenousPharmascience IncNot applicableNot applicableCanada
PMS-midazolamLiquid5 mgIntramuscular; IntravenousPharmascience IncNot applicableNot applicableCanada
Versed Inj 1mg/mlLiquid1 mgIntramuscular; IntravenousHoffmann La Roche Limited1989-12-312004-07-07Canada
Versed Inj 5mg/mlLiquid5 mgIntramuscular; IntravenousHoffmann La Roche Limited1988-12-312004-06-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-midazolam Injectable 1 mg/mlLiquid1 mgIntramuscular; IntravenousApotex Inc2001-04-102013-08-02Canada
Apo-midazolam Injectable 5 mg/mlLiquid5 mgIntramuscular; IntravenousApotex Inc2001-04-102013-08-02Canada
MidazolamInjection1 mg/mLIntramuscular; IntravenousAkorn, Inc.2005-05-06Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousCardinal Health2000-06-20Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousCardinal Health2000-07-14Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-10Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-06-20Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp.2000-06-20Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousAkorn, Inc.2005-05-06Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousCardinal Health2000-06-20Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, LLC2000-07-14Not applicableUs
MidazolamInjection, solution2 mg/2mLIntramuscular; IntravenousBd Rx2014-10-03Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousCaraco Pharmaceutical Laboratories, Ltd.2012-08-08Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousCardinal Health2000-06-20Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, LLC2000-07-10Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousBd Rx2014-10-03Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousCaraco Pharmaceutical Laboratories, Ltd.2012-08-08Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-06-20Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousCardinal Health2000-06-20Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection, solution10 mg/2mLIntramuscular; IntravenousBd Rx2014-10-03Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousCardinal Health2000-07-14Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralRanbaxy Pharmaceuticlas Inc2002-07-05Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralPrecision Dose Inc.2015-05-26Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousHospira, Inc.2002-07-22Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralRoxane Laboratories, Inc2002-04-30Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2006-12-12Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralPaddock Laboratories, LLC2005-05-02Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousWockhardt USA LLC.2008-05-30Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-03-042015-12-29Us
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousHospira, Inc.2000-06-20Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousCardinal Health2002-07-22Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousWockhardt Limited2008-11-10Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousHeritage Pharmaceuticals2016-11-07Not applicableUs
Midazolam HydrochlorideInjection10 mg/2mLIntramuscular; IntravenousCardinal Health2000-06-21Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousHospira, Inc.2002-06-13Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralPrecision Dose Inc.2015-05-26Not applicableUs
Midazolam HydrochlorideInjection2 mg/2mLIntramuscular; IntravenousCardinal Health2000-06-21Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousWockhardt Limited2008-05-30Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousWockhardt USA LLC.2008-11-10Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-03-042015-12-29Us
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousHospira, Inc.2000-06-20Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousCardinal Health2002-07-22Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralAtlantic Biologicals Corps2002-04-30Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousHeritage Pharmaceuticals2016-11-08Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousCardinal Health2010-03-04Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousHospira, Inc.2002-06-13Not applicableUs
Midazolam HydrochlorideSyrup2 mg/mLOralAtlantic Biologicals Corps2002-07-05Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousDispensing Solutions, Inc.2011-05-02Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousCardinal Health2000-06-21Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousWockhardt Limited2008-05-30Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousCardinal Health2002-06-13Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousWockhardt USA LLC.2008-11-10Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousGland Pharma Limited2012-06-012016-12-02Us
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousCardinal Health2010-03-04Not applicableUs
Midazolam HydrochlorideSyrup10 mg/5mLOralPrecision Dose Inc.2010-10-112016-08-31Us
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousCardinal Health2005-08-03Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousHospira, Inc.2002-07-22Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousWockhardt USA LLC.2008-05-30Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousDispensing Solutions, Inc.2011-05-03Not applicableUs
Midazolam HydrochlorideInjection5 mg/mLIntramuscular; IntravenousCardinal Health2000-06-21Not applicableUs
Midazolam HydrochlorideInjection1 mg/mLIntramuscular; IntravenousWockhardt Limited2008-11-10Not applicableUs
Midazolam HydrochlorideInjection, solution1 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolam HydrochlorideInjection, solution5 mg/mLIntramuscular; IntravenousGland Pharma Limited2012-06-012016-12-02Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Midazolam HClInjection, solution.5 mg/mLIntravenousCantrell Drug Company2013-01-30Not applicableUs
Midazolam HClInjection, solution1 mg/mLIntravenousCantrell Drug Company2010-08-02Not applicableUs
International Brands
NameCompany
AnquilGeneral Pharma
BenzosedPharmaceutical
DalamRichmond
DamizolSpecifar
DemizolamDem Ilaç
DoricumRoche
DormicumRoche
DormidScott
DormipronChalver
DormireCristália
DormitolSquare
DormixalDemo
DormonidRoche
DrimnorthNorthia
EpistatusIFET
FlormidalGalenika
FulsedRanbaxy
Fulsed InjectionTerapia
GarenBio-Pharma
GobbizolamGobbi
HipnazolamEMS
HipnozPharos
HypnofastIncepta
HypnovelRoche
IpnovelRoche
NocturnaLafi
SetamRimsa
TalentumFisiopharma
TerapSanitas
VersedRoche
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Midazolam Hydrochloride
Thumb
  • InChI Key: PLYSCVSCYOQVRP-UHFFFAOYSA-N
  • Monoisotopic Mass: 361.054881082
  • Average Mass: 362.228
DBSALT000118
Categories
UNIIR60L0SM5BC
CAS number59467-70-8
WeightAverage: 325.767
Monoisotopic: 325.078203343
Chemical FormulaC18H13ClFN3
InChI KeyDDLIGBOFAVUZHB-UHFFFAOYSA-N
InChI
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
IUPAC Name
12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Pharmacology
IndicationThe midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia.
Structured Indications
PharmacodynamicsMidazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.
Mechanism of actionIt is thought that the actions of benzodiazepines such as midazolam are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines increase the activity of GABA, thereby producing a calming effect, relaxing skeletal muscles, and inducing sleep. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Gamma-aminobutyric acid receptor subunit thetaProteinyes
potentiator
HumanQ9UN88 details
Related Articles
AbsorptionRapidly absorbed after oral administration. The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%. The absolute bioavailability, if given intramuscularly (IM), is greater than 90%. Cmax, IM = 90 ng/mL; Tmax, IM = 0.5 hours. Following IM administered, Cmax for midazolam and its 1-hydroxy metabolite were approxiately one-half of those achieved after intravenous injection.
Volume of distribution
  • 1.24 to 2.02 L/kg [pediatric patients (6 months to <16 years) receiving 0.15 mg/kg IV midazolam,]
  • 1 to 3.1 L/kg [intravenously administered, healthy adults]
    Female gender, old age, and obesity may increase the volume of distribution. Midazolam may also cross the placenta and has been detected in human milk and cerebrospinal fluid.
Protein binding97% protein bound.
Metabolism

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam (also known as 1-hydroxy-midazolam), and 4-hydroxymidazolam (makes up 5% or less of the biotransformation products). 1-hydroxy-midazolam is at least as potent as the parent compound and may contributed to the overall activity of midazolam. In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. It also undergoes N-glucuronidation via UGT1A4.

SubstrateEnzymesProduct
Midazolam
Alpha-hydroxymidazolamDetails
Midazolam
4-hydroxymidazolamDetails
Route of eliminationMidazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, α-hydroxymidazolam, followed by glucuronidation of the α–hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The α- hydroxymidazolam glucuronide is then excreted in urine. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates. The amount of midazolam excreted unchanged in the urine when given intravenously is less than 0.5%. 45% to 57% of the dose was excreted in the urine as 1-hydroxymethyl midazolam conjugate.
Half lifeIntravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)
Clearance
  • 9.3 to 11 mL/min/kg [pediatric patients (6 months to <16 years old)]
  • 0.25 to 0.54 L/hr/kg [intravenous, healthy adults]
ToxicityLD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Midazolam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Midazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Midazolam.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Midazolam.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Midazolam.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Midazolam is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Midazolam.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.Approved, Investigational
AlbendazoleThe serum concentration of Midazolam can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Midazolam can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Midazolam can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Midazolam can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Midazolam.Approved, Investigational
AlogliptinThe serum concentration of Midazolam can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Midazolam is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.Approved, Illicit, Investigational
AmantadineThe serum concentration of Midazolam can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Midazolam.Approved, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Midazolam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
Aminohippuric acidThe serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Midazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.Approved
AmlodipineThe serum concentration of Midazolam can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Midazolam can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Midazolam can be increased when it is combined with Amsacrine.Approved
Antithrombin III humanThe serum concentration of Midazolam can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Midazolam can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Midazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Midazolam can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Midazolam can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine.Approved
AstemizoleThe serum concentration of Midazolam can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Midazolam can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Midazolam can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Midazolam.Approved
AtomoxetineThe metabolism of Midazolam can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Midazolam.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Azaperone.Vet Approved
AzelastineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Midazolam can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Midazolam can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Midazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.Illicit
BatimastatThe serum concentration of Midazolam can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Midazolam can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Midazolam is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Midazolam can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Midazolam can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Midazolam can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Midazolam.Approved, Vet Approved
BexaroteneThe serum concentration of Midazolam can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Midazolam can be increased when it is combined with Bi201335.Investigational
BiperidenThe serum concentration of Midazolam can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Midazolam can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Midazolam can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Midazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Midazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Midazolam.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.Approved, Investigational
BuprenorphineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Midazolam can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Midazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Midazolam.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Midazolam.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.Approved
CandesartanThe serum concentration of Midazolam can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Midazolam can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Midazolam can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Midazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.Approved
CarbomycinThe serum concentration of Midazolam can be increased when it is combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Midazolam.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.Approved
CarvedilolThe serum concentration of Midazolam can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Midazolam can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Midazolam can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Midazolam.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Midazolam can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.Approved, Vet Approved
ChlorpropamideThe serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Midazolam can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Midazolam can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Midazolam can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Midazolam can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Midazolam can be decreased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Midazolam.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Midazolam.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Midazolam.Approved
ClarithromycinThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Midazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Midazolam.Approved, Illicit
ClofazimineThe serum concentration of Midazolam can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Midazolam.Approved, Investigational
ClomipramineThe serum concentration of Midazolam can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Midazolam.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.Approved, Illicit
ClotrimazoleThe metabolism of Midazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Clozapine.Approved
CobicistatThe serum concentration of Midazolam can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Midazolam.Approved
CocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Midazolam.Approved
ColforsinThe serum concentration of Midazolam can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Midazolam can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Midazolam.Approved
CrizotinibThe metabolism of Midazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Midazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.Approved
DabrafenibThe serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Midazolam can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Midazolam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Midazolam can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Midazolam.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Midazolam.Approved
DeferasiroxThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Midazolam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Midazolam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.Approved
DesipramineThe serum concentration of Midazolam can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Midazolam can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam.Approved, Vet Approved
DextromethorphanThe serum concentration of Midazolam can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Midazolam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Midazolam can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Midazolam.Approved
DigoxinThe serum concentration of Midazolam can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Midazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam.Illicit
DiltiazemThe metabolism of Midazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Midazolam.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Midazolam is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Midazolam can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Midazolam can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Midazolam.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Midazolam.Approved, Investigational
DoxycyclineThe metabolism of Midazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Midazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
DronedaroneThe metabolism of Midazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.Approved
DyphyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.Approved
EcabetThe serum concentration of Midazolam can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Midazolam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Midazolam can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Midazolam can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Midazolam can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Midazolam can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Midazolam.Approved, Investigational
EnalaprilThe serum concentration of Midazolam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Midazolam can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Midazolam can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Midazolam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Midazolam.Approved, Investigational
ErgonovineThe serum concentration of Midazolam can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Midazolam can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Midazolam.Approved, Investigational
ErythromycinThe serum concentration of Midazolam can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Midazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Midazolam.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Midazolam can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Midazolam.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Midazolam.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.Approved
EthanolMidazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Midazolam.Approved
EtorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Midazolam can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Midazolam.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Midazolam.Approved
EzogabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.Approved
FelodipineThe serum concentration of Midazolam can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Midazolam.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Midazolam.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.Approved
FluconazoleThe metabolism of Midazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe serum concentration of Midazolam can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Midazolam can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Midazolam can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Midazolam can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Midazolam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Midazolam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Midazolam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Midazolam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Midazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Midazolam is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Midazolam can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Midazolam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Midazolam.Approved, Investigational
GeldanamycinThe serum concentration of Midazolam can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Midazolam.Approved
GenisteinThe serum concentration of Midazolam can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Gepirone.Investigational
Ginkgo bilobaThe serum concentration of Midazolam can be decreased when it is combined with Ginkgo biloba.Approved, Nutraceutical
GlutethimideThe risk or severity of adverse effects can be increased when Midazolam is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Midazolam can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Midazolam can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Midazolam can be increased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Midazolam can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Midazolam.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Midazolam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Midazolam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.Approved
HirulogThe serum concentration of Midazolam can be increased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Midazolam.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Midazolam.Approved
IdelalisibThe serum concentration of Midazolam can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Midazolam can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Midazolam can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Midazolam can be increased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Midazolam.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Midazolam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Midazolam can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Midazolam.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Midazolam.Approved, Investigational
IsavuconazoniumThe metabolism of Midazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Midazolam can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Midazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Midazolam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Midazolam can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Midazolam.Approved, Vet Approved
IxazomibThe serum concentration of Midazolam can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Midazolam can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Midazolam can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Midazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Midazolam can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Midazolam can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Midazolam can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Midazolam.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Midazolam.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Midazolam.Approved, Investigational
LapatinibThe serum concentration of Midazolam can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Midazolam.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Midazolam.Approved
LepirudinThe serum concentration of Midazolam can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Midazolam.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Midazolam can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Midazolam can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Midazolam can be increased when it is combined with Linagliptin.Approved
LiothyronineThe serum concentration of Midazolam can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Midazolam can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Midazolam can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Midazolam can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Midazolam.Approved
LopinavirThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Midazolam can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Midazolam.Approved
LovastatinThe metabolism of Midazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Midazolam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Midazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Midazolam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Midazolam.Approved, Investigational
MaprotilineThe serum concentration of Midazolam can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Midazolam can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Midazolam can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Midazolam can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Midazolam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Midazolam can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.Approved
MethadoneMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Midazolam.Approved
MethotrimeprazineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Midazolam.Approved, Investigational
MetyrosineMidazolam may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Midazolam can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Midazolam can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Midazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Midazolam.Approved
MirtazapineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Midazolam can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Midazolam can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam.Approved, Investigational
ModafinilThe serum concentration of Midazolam can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Midazolam can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Midazolam.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Midazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Midazolam.Approved
NafamostatThe serum concentration of Midazolam can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Midazolam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Midazolam.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Midazolam.Approved, Vet Approved
NaltrexoneThe serum concentration of Midazolam can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Midazolam can be increased when it is combined with Naringenin.Experimental
NCX 4016The serum concentration of Midazolam can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Midazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Midazolam can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Midazolam can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Midazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Midazolam can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Midazolam.Approved
NifedipineThe serum concentration of Midazolam can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Midazolam can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Midazolam.Approved
NisoldipineThe serum concentration of Midazolam can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Midazolam can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Midazolam can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Midazolam can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Midazolam.Approved
NorethisteroneThe serum concentration of Midazolam can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.Approved, Investigational
OlaparibThe metabolism of Midazolam can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Midazolam can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Midazolam can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Midazolam.Approved
OmeprazoleThe serum concentration of Midazolam can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Opium.Approved, Illicit
OrphenadrineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Midazolam can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Midazolam can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Midazolam can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.Approved, Vet Approved
PalbociclibThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Midazolam.Approved, Investigational
PantoprazoleThe serum concentration of Midazolam can be increased when it is combined with Pantoprazole.Approved
ParaldehydeMidazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Midazolam can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.Approved, Vet Approved
PentobarbitalThe metabolism of Midazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Perazine.Investigational
PerindoprilThe serum concentration of Midazolam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.Approved
PhenobarbitalThe metabolism of Midazolam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Midazolam.Approved, Vet Approved
PhosphoramidonThe serum concentration of Midazolam can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Midazolam can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Midazolam is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Midazolam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Midazolam is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Midazolam.Approved
PosaconazoleThe metabolism of Midazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleMidazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Midazolam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Midazolam.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Midazolam.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Midazolam can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Midazolam can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Midazolam can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.Approved, Vet Approved
ProgesteroneThe serum concentration of Midazolam can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.Approved, Vet Approved
PromethazineThe serum concentration of Midazolam can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Midazolam can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.Approved, Vet Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Midazolam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Midazolam.Approved, Investigational
ProtriptylineThe serum concentration of Midazolam can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Midazolam.Approved
PSD502The risk or severity of adverse effects can be increased when Midazolam is combined with PSD502.Investigational
QuazepamThe serum concentration of Midazolam can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Midazolam can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.Approved
QuinacrineThe serum concentration of Midazolam can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Midazolam can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Midazolam.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Midazolam.Approved
RacecadotrilThe serum concentration of Midazolam can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Midazolam can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Midazolam.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Midazolam.Approved, Investigational
ReboxetineThe serum concentration of Midazolam can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Midazolam can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.Approved
RemikirenThe serum concentration of Midazolam can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam.Approved, Withdrawn
ReserpineThe serum concentration of Midazolam can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Midazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Midazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Midazolam can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Midazolam.Approved, Investigational
RilpivirineThe serum concentration of Midazolam can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Midazolam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Midazolam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Midazolam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.Approved
RolapitantThe serum concentration of Midazolam can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Midazolam.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Romifidine.Vet Approved
RopiniroleMidazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam.Approved
RotigotineMidazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Midazolam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Midazolam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Midazolam is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Midazolam.Approved, Vet Approved
SaquinavirThe serum concentration of Midazolam can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Midazolam can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Midazolam can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.Approved, Vet Approved
SelegilineThe serum concentration of Midazolam can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Midazolam.Approved
SertindoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole.Approved, Withdrawn
SertralineThe serum concentration of Midazolam can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Midazolam can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Midazolam.Approved
SiltuximabThe serum concentration of Midazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Midazolam can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Midazolam can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Midazolam can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Midazolam can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateMidazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Midazolam.Approved
SolithromycinThe serum concentration of Midazolam can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Midazolam.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Midazolam.Experimental
SpiraprilThe serum concentration of Midazolam can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Midazolam can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Midazolam can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Midazolam can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Midazolam can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Midazolam can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Midazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam.Approved
SumatriptanThe serum concentration of Midazolam can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Midazolam can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantMidazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Midazolam can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Midazolam can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Midazolam.Approved
TandospironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Midazolam.Approved
TeduglutideThe serum concentration of Midazolam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe serum concentration of Midazolam can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Midazolam can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Midazolam can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.Approved
TemocaprilThe serum concentration of Midazolam can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.Approved
TerazosinThe serum concentration of Midazolam can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Midazolam can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Midazolam can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Midazolam can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin.Investigational
ThalidomideMidazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Midazolam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.Approved
ThiorphanThe serum concentration of Midazolam can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Midazolam can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.Approved
TiclopidineThe metabolism of Midazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Midazolam.Approved
TipranavirThe serum concentration of Midazolam can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Midazolam.Approved
TopiramateThe risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Midazolam.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Midazolam.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.Approved, Investigational
TrandolaprilThe serum concentration of Midazolam can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Midazolam.Approved
TrazodoneThe serum concentration of Midazolam can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.Approved
TrifluoperazineThe serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Midazolam can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Midazolam can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Midazolam can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Midazolam can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Midazolam can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Midazolam is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Midazolam can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Midazolam.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Midazolam.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Midazolam.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Midazolam.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Midazolam.Approved
VenlafaxineThe metabolism of Midazolam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Midazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin.Approved
VildagliptinThe serum concentration of Midazolam can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Midazolam.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Midazolam.Approved, Investigational
VinorelbineThe serum concentration of Midazolam can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Midazolam.Approved
VoriconazoleThe metabolism of Midazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.Approved
XimelagatranThe serum concentration of Midazolam can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Xylazine.Vet Approved
Ym150The serum concentration of Midazolam can be increased when it is combined with Ym150.Investigational
YohimbineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Midazolam.Approved
ZimelidineThe serum concentration of Midazolam can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Midazolam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zolazepam.Vet Approved
ZolpidemMidazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Midazolam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit juice slows the product's absorption and significantly increases its bioavailability.
References
Synthesis Reference

Madhup K. Dhaon, “Process for the preparation of midazolam.” U.S. Patent US6262260, issued August, 1979.

US6262260
General References
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]
  2. Isojarvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:80-92. [PubMed:10030438 ]
  3. Garratt JC, Gent JP, Feely M, Haigh JR: Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential? Eur J Pharmacol. 1988 Jan 5;145(1):75-80. [PubMed:2894998 ]
  4. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
  5. Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115 ]
External Links
ATC CodesN05CD08
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9724
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.5074
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7476
CYP450 2C9 substrateNon-substrate0.7366
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7194
CYP450 1A2 substrateInhibitor0.8586
CYP450 2C9 inhibitorInhibitor0.7132
CYP450 2D6 inhibitorNon-inhibitor0.6887
CYP450 2C19 inhibitorInhibitor0.6554
CYP450 3A4 inhibitorNon-inhibitor0.5214
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9001
Ames testNon AMES toxic0.8024
CarcinogenicityNon-carcinogens0.7703
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1488 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.7379
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Astrazeneca pharmaceuticals lp
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • International medicated systems ltd
  • International medication systems ltd
  • Taylor pharmaceuticals
  • Wockhardt ltd
  • Hlr technology
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Paddock laboratories inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous1 mg
LiquidIntramuscular; Intravenous5 mg
SolutionBuccal10 mg
SolutionBuccal2.5 mg
SolutionBuccal5 mg
SolutionBuccal7.5 mg
InjectionIntramuscular; Intravenous1 mg/mL
InjectionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/2mL
Injection, solutionIntramuscular; Intravenous2 mg/2mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous1 mg/mL
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous2 mg/2mL
Injection, solutionIntramuscular; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
SyrupOral10 mg/5mL
SyrupOral2 mg/mL
SolutionIntramuscular; Intravenous1 mg
SolutionIntramuscular; Intravenous5 mg
Prices
Unit descriptionCostUnit
Midazolam 5 mg/ml3.9USD ml
Midazolam-nacl 2 mg/ml inj2.31USD ml
Midazolam hcl 5 mg/ml vial1.18USD ml
Midazolam-nacl 1 mg/ml inj1.13USD ml
Midazolam hcl 2 mg/ml syrup1.08USD ml
Midazolam 1 mg/ml isecure syr0.73USD ml
Midazolam hcl 1 mg/ml vial0.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point159 °CPhysProp
water solubility0.024 mg/mLThorsteinn Loftsson and Dagný Hreinsdóttir, 2006
Predicted Properties
PropertyValueSource
Water Solubility0.00987 mg/mLALOGPS
logP3.89ALOGPS
logP3.33ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)6.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area30.18 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.43 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03di-3839000000-42781254e15bcd5b31b6View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazo[1,5-a][1,4]benzodiazepines. These are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct ParentImidazo[1,5-a][1,4]benzodiazepines
Alternative Parents
Substituents
  • Imidazo[1,5-a][1,4]benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Para-diazepine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A: Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 Oct;5(5):415-42. [PubMed:15544435 ]
  5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  6. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827 ]
  7. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44. [PubMed:12814972 ]
  3. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994 Nov;73(5):658-61. [PubMed:7826796 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Apr 29;47(9):1643-53. [PubMed:8185679 ]
  3. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos. 1996 Sep;24(9):940-7. [PubMed:8886602 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA: Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9. [PubMed:9732386 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP4B1
Uniprot ID:
P13584
Molecular Weight:
58990.64 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G: Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos. 2008 May;36(5):851-62. doi: 10.1124/dmd.107.019539. Epub 2008 Feb 6. [PubMed:18256203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [PubMed:9822896 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  6. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  7. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23